Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma

By afschroeder • August 15, 2025

Meyer T, Finn RS, Borad M, Mahipal A, Edeline J, Houot R, Hausner PF, Hollebecque A, Goyal L, Frigault M, Jeffry Evans TR, Wong KM, Tan BR, Mitry E, Sarker D, Feun L, El-Rayes B, Thistlethwaite F, Kaseb A, Alese O, Jin Z, Cirillo C, Bruix J, Roddie C, Noto P, Fayngerts S, Cristiani S, Sampson J, Bai J, Isabelle M, Broad R, Sun A, Norry E, Sangro B. Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma. J Hepatol. 2025 Aug 12:S0168-8278(25)02404-3. doi: 10.1016/j.jhep.2025.07.033. Epub ahead of print. PMID: 40812667.

Tags: Adoptive T-cell therapy, alpha-fetoprotein, Hematology/Oncology, Hepatocellular carcinoma, immunotherapy, Publications, T-cell receptor T-cell therapy

RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial

Chugh R, Singh A, Andelkovic V, Mallick AB, Brockstein B, Bui N, Chawla S, Choy E, Davis LE, Gounder M, Haddadin S, Kasper B, Kim[...]

Androgen receptor inhibitor double therapies in the management of metastatic castration-sensitive prostate cancer: a cost-effectiveness analysis

Padula WV, Cohen BG, Steel P, Appukkuttan S, Kalayeh B, Rettig M. Androgen receptor inhibitor double therapies in the management of metastatic castration-sensitive prostate cancer:[...]

tRNA dosage regulates lineage dependency and resistance in prostate cancer

Kim YS, Arora S, Young D, Tsou A, Shiuan A, Wladyka CL, Rudoy D, Kim JY, Waters JA, Schuster SL, Coleman IM, Kapur M, Sobczyk[...]